3-(2,6-Dichlorophenyl)-2,3-Dihydro-1-Methyl-7-[[3-Methyl-4-(1-Methyl-4-Piperidinyl)Phenyl]Amino]-Pyrimido[4,5-D]Pyrimidin-4(1H)-One

2 trials 2 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

2 Recruiting

0 Completed trials

1 Sponsors

3 Countries

Phase I/II

Phase I

Phase I/II: 1 Phase I: 1

Indications tested

Sponsors using this IMP

Debiopharm International S.A. 2

All trials

2 total

A phase 1 trial to study how safe and tolerable Lunresertib is, alone or in Combination with RP-3500 or Debio 0123, when administered in pat… Recruiting

2023-510063-35-00 Phase I 3 countries Debiopharm International S.A.
A Study of Debio 0123 in Combination with Temozolomide in Adult Participants with Recurrent or Progressive Glioblastoma and of Debio 0123 in… Recruiting

2022-502156-31-00 Phase I/II 1 country Debiopharm International S.A.

Showing 1–2 of 2 trials

← All drugs A–Z